A Phase I Open Label Study Investigating the Combination of KD018 and Sorafenib (Nexavar) in Patients With Advanced Hepatocellular Carcinoma
Latest Information Update: 18 Sep 2021
At a glance
- Drugs KD 018 (Primary) ; Sorafenib
- Indications Liver cancer
- Focus Adverse reactions
- 27 Jan 2021 Biomarkers information updated
- 29 May 2013 Planned end date changed from 1 Dec 2017 to 1 Dec 2018 as reported by ClinicalTrials.gov.
- 01 May 2013 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.